RenovoRx, Inc. (NASDAQ: RNXT) disclosed an insider acquisition by Chief Executive Officer Shaun Bagai on March 20, 2026. Documents show that The Bagai Family Trust bought 24,300 shares of the company’s common stock in a transaction the filing lists with a total consideration of $0.
In the same filing, The Bagai Family Trust also took ownership of 12,150 warrants. Those instruments are exercisable immediately at a strike price of $1.9326. The warrants carry an expiration date of March 30, 2029, unless they terminate earlier - specifically, they will expire 30 days after the company reports product sales revenue of at least $1.5 million for any calendar quarter.
At the time the insider transactions were reported, RNXT shares were trading at $1.08 and the company’s market capitalization was $50.05 million. The stock has risen 28.6% year-to-date. Separately, analyst and data-provider notes state that RenovoRx’s balance sheet shows more cash than debt, according to InvestingPro. The company also has an earnings announcement scheduled for March 30, which the filing characterizes as occurring five days after the insider activity.
These insider transactions arrive against a backdrop of corporate financing and fresh analyst interest. RenovoRx said it completed a securities purchase agreement with institutional investors, raising approximately $10 million in a private placement. The placement was led by life science institutional investors and included participation from members of RenovoRx’s executive management team and its board.
Konik Capital Partners, LLC, a division of T.R. Winston & Company, served as the sole placement agent for that financing, according to company disclosures. In addition to the capital raise, Jones Trading initiated coverage on RenovoRx with a Buy rating and set a price target of $8.00.
Company materials referenced in filings highlight RenovoRx’s FDA-cleared dual-balloon catheter, known as RenovoCath, which the company describes as intended to improve delivery of therapeutic agents to tumors. The combination of insider stock and warrant activity, new financing, and analyst coverage frames the near-term newsflow for investors watching the company ahead of its upcoming quarterly report.
Context note: The insider purchase and warrant issuance were reported in company filings. Other reported items include the private placement, placement agent, analyst initiation, and the FDA-clearance status of RenovoCath as set out above.